Harder FN, Jungmann F, Kaissis GA, Lohoefer FK, Ziegelmayer S, Havel D, Quante M, Reichert M, Schmid RM, Demir IE, Friess H, Wildgruber M, Siveke J, Muckenhuber A, Steiger K, Weichert W, Rauscher I, Eiber M, Makowski MR, Braren RF (2021)
Publication Type: Journal article
Publication year: 2021
Book Volume: 11
Article Number: 70
Journal Issue: 1
DOI: 10.1186/s13550-021-00808-4
Purpose: In this prospective exploratory study, we evaluated the feasibility of [18F]fluorodeoxyglucose ([18F]FDG) PET/MRI-based chemotherapy response prediction in pancreatic ductal adenocarcinoma at two weeks upon therapy onset. Material and methods: In a mixed cohort, seventeen patients treated with chemotherapy in neoadjuvant or palliative intent were enrolled. All patients were imaged by [18F]FDG PET/MRI before and two weeks after onset of chemotherapy. Response per RECIST1.1 was then assessed at 3 months [18F]FDG PET/MRI-derived parameters (MTV
APA:
Harder, F.N., Jungmann, F., Kaissis, G.A., Lohoefer, F.K., Ziegelmayer, S., Havel, D.,... Braren, R.F. (2021). [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Research, 11(1). https://doi.org/10.1186/s13550-021-00808-4
MLA:
Harder, Felix N., et al. "[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma." EJNMMI Research 11.1 (2021).
BibTeX: Download